- Japan Third Quarter GDP Jumps; 2010 Growth May Slow
- Analysis: APEC Nations Back Face-Saving Climate Plan
- Shift Into High-Quality Stocks Could Move Market Higher
- Drug Study Questions Effectiveness of Merck's Drugs
- Military Arms Race Dominates Dubai Air Show
- Buffett: I Haven't Bought AMEX Shares in Years
- Disaster Film '2012' Drowns Rivals at Box Office
- Cities With the Most Home Price Reductions
- Cramer: 5 Earnings Reports to Watch Next Week
- CNBC Video: Warren Buffett & Bill Gates - Keeping American Great
- U.S. Stocks Rally for the Second Straight Week
- Dollar is Not Plunging—So 'Calm Down': Market Strategist
- Strategists Say Markets Have More Upside — But How Much?
- Hirschhorn: Risk-Averse Traders
- Roginsky: A Funny Thing Happened on the Way to Financial Reform
- This Year's Biggest Thanksgiving Leftover: Cash
- TV Series Inks Unique Deal For Fight
- First Time Buyers Rescue Housing: Realtors
MOST SHARED
- U.S. May Wind Up Green With Envy
- Japan Third Quarter GDP Jumps; 2010 Growth May Slow
- Warren Buffett to CNBC: 'I Haven't Bought American Express In Years'
- Analysis: APEC Nations Back Face-Saving Climate Plan
- Disaster Film '2012' Drowns Rivals at Box Office
- Dipping Into Green Investing
- For Investors, The New Green Looks To Be White
- The Cost of Thanksgiving Dinner 2009
- Sustainability Indices Sprouting Up
- CNBC TRANSCRIPT: Warren Buffett & Bill Gates - Keeping America Great
Text Size 
The American Heart Association issued new guidelines for Pfizer's Celebrex, advising doctors the painkiller should only be used as a last resort on patients who have heart disease or a risk of developing it, CNBC's Mike Huckman reported.
Celebrex is a COX-2 inhibitor and it's the only drug in that class still on the market in the U.S. after Merck pulled Vioxx and Pfizer pulled Bextra off pharmacy shelves.
In a prepared statement, Pfizer [PFE
Loading...
()
] told Huckman the AHA's recommendations are "oversimplified" and "not based on robust clinical data … and may further confuse patients."
But the American Heart Association says a recent analysis show that COX-2 drugs increase the risk of having a heart attack by 86%. The drug already has a so-called black box warning label, the FDA's toughest warning of heart risk since 2005.
Dr. Elliott Antman, lead author of the AHA's scientific statement and a professor at Harvard Medical School, makes no bones about Pfizer's Celebrex.
"It is not a safe drug," says Antman. "It is not a drug we should turn to as a first line treatment for management of pain in a patient with heart disease. We're actually recommending that it be the last line of treatment."
Antman said heart disease patients should be instructed to diet and exercise and failing that, to try aspirin first, then Tylenol or Aleve.
The most infamous of the COX-2 class is Vioxx, which was pulled from the market by Merck [MRK
Loading...
()
] in 2004 after it was discovered that the drug raised the risk of heart attacks and strokes.
After Vioxx fears eventually subsided, sales of Celebrex rebounded last year with 2006 sales of $2 billion. Pfizer has said it expects the rebound to continue for the franchise again this year.
Print
Email
- Where, what, how.
- Warren Buffett and Bill Gates spoke to Columbia students, and Buffett made the students a startling offer.
- For the chief of cable company Comcast, growth has been about making deals – generally very large deals.
- Some companies may start using insurance to shift carbon risk from their balance sheets to maybe... yours?
- The president and founder of Genesis Today wants to improve America’s health, and thinks Wal-Mart can help.
- Switzerland's privacy watchdog is taking legal action to force Google to make changes to its Street View service.
Data is a real-time snapshot *Data is delayed at least 15 minutes